Stented and Improving: How Long Does the Antibiotic Course Actually Run
A single patient, three days into recovery from an infected, obstructed kidney. The disagreement isn't about whether he's improving — it's about what happens to his antibiotics for the three weeks between now and the stone removal his surgical schedule, not his infection, is actually dictating.
J.K., a 45-year-old man who works as a forklift operator, spent four days telling himself the ache in his right flank was just how his back felt after a run of overtime shifts before the fever made it impossible to keep believing that. He arrived with a temperature of 102.4, exquisite right costovertebral tenderness, and a CT showing an 8mm proximal ureteral stone with high-grade hydronephrosis — an obstructed, infected kidney, treated as the urologic emergency it is with an urgent ureteral stent placed within hours of arrival. He has no prior stone history, no diabetes, and no structural abnormality beyond the stone itself; this is a first, isolated event rather than a chronic pattern. Three days later, decompressed and on IV ceftriaxone since admission, he looks like a different patient: afebrile for thirty-six hours, flank pain resolving, white count trending down from 18.2 to 11.6. The stone itself is still there, still obstructing on some level even with the stent bypassing it, and definitive treatment — ureteroscopy with laser lithotripsy — is scheduled in roughly three weeks, the earliest slot the surgical schedule allows.
What happens to his antibiotics between now and that date is the actual question, and it turns out to rest on surprisingly little direct evidence. AUA and European guidelines agree that stone removal should wait until infection is adequately treated, but neither defines what "adequately treated" means in days. A 2023 Urology study by Orr et al., following 215 patients through exactly this decompression-to-stone-treatment interval, found that neither the duration of antibiotics nor the length of time before definitive treatment predicted who developed urosepsis afterward — a finding that cuts against both sides of tonight's argument equally, since it means neither a short course nor a long one has been shown to be the safer choice.
On the ward, three days after stent placement
Keep him on oral ciprofloxacin straight through to the day of surgery. Béïque and colleagues in Ottawa compared exactly this — a defined course with an antibiotic-free gap versus continuing until stone removal — in patients decompressed for an infected obstruction, and the interrupted group ran a more than 3-fold higher rate of recurrent infection before their stone came out. I'll name the weakness before you do: that difference didn't reach statistical significance, and the authors call the study underpowered. But his stone is still there, and this isn't a source-controlled infection the way a drained abscess is.
Three weeks of ciprofloxacin for a patient who's already afebrile with a falling white count is a real cost, not a free margin of safety. Eliakim-Raz's meta-analysis found seven days or less noninferior to longer courses for pyelonephritis and septic urinary infection broadly — and Orr et al.'s own 2023 series of 215 patients in this specific decompression-to-surgery interval found antibiotic duration itself didn't predict who developed urosepsis afterward. That cuts against extending his course just as much as it cuts against stopping early.
And I'd press the weakness harder than he conceded it. A 3-fold ratio that doesn't clear significance in an admittedly underpowered retrospective study isn't a result we commit three weeks of ciprofloxacin to — it's a reason to run a better study. The same paper reports no significant difference between the groups in new resistant organisms, C. difficile, or adverse events, and its authors say plainly they may have lacked the power to detect one. So it can't reassure us about the cost of his strategy either. It is underpowered in both directions.
I don't think either of you is going to resolve the duration question with what's actually been studied. But there's a subgroup finding worth naming, with its provenance attached: in a separate single-center cohort of bacteremic stone patients — reported as a conference abstract, not a peer-reviewed paper — the excess treatment failure in the antibiotic-free group disappeared in the subset whose stone came out within six weeks of decompression. J.K. isn't documented bacteremic, so he only partly matches that population. But his surgery is scheduled at three weeks, well inside that window. Maybe the actual fix isn't picking a duration theory — it's making sure that three-week date holds and doesn't slip.
Agreed: continue oral ciprofloxacin through the scheduled surgery date, with urology explicitly asked to flag the team immediately if the three-week slot is at risk of slipping.
Not agreed, and left open rather than resolved:
The real lesson here is that surgical scheduling, not antibiotic duration, is the lever that actually matters — worth naming explicitly the next time this exact situation comes up.
The stewardship pharmacist's caution about three weeks of antibiotics without direct trial support remains a live, unaddressed cost of tonight's plan.
Nobody claimed the underlying duration question was settled; the plan optimizes for J.K.'s specific situation — an obstruction not yet removed — without resolving which general theory of duration is correct.